Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Depo-Medrol, Medrol Acetate, Medrol. Every FDA application for this active ingredient: 3 branded and 22 generic.
As of Nov 16, 2026, FDA lists 25 applications for Methylprednisolone Acetate (sold as Depo-Medrol, Medrol Acetate, Medrol), first approved May 27, 1959, with 0 new uses approved and 0 published complete response letters.
First approved: May 27, 1959
Applications: 25
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $15.3M
Shortage: Current
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Depo-Medrol
Part B
$15.0M
+46%
1,332,132
Methylprednisolone Acetate
Part D
$223K
+1%
8,305
Depo-Medrol
Part D
$40K
+59%
1,284
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
METHYLPREDNISOLONE 16 MG TAB: $1.48 per unitGeneric · -9% in a year
METHYLPREDNISOLONE 32 MG TAB: $2.55 per unitGeneric · +1% in a year
METHYLPREDNISOLONE 4 MG DOSEPK: $0.144 per unitGeneric · +16% in a year
METHYLPREDNISOLONE 4 MG TABLET: $0.116 per unitGeneric · -21% in a year
METHYLPREDNISOLONE 40 MG/ML VL: $7.49 per MLGeneric · -8% in a year
METHYLPREDNISOLONE 400 MG/10 ML: $5.57 per MLGeneric · -3% in a year
METHYLPREDNISOLONE 8 MG TABLET: $0.923 per unitGeneric · -9% in a year
METHYLPREDNISOLONE 80 MG/ML VL: $11.92 per MLGeneric · +5% in a year
DEPO-MEDROL 40 MG/ML VIAL: $6.90 per MLBrand · -4% in a year
DEPO-MEDROL 80 MG/ML VIAL: $11.64 per MLBrand · +42% in a year
MEDROL 2 MG TABLET: $1.57 per unitBrand · new this year
MEDROL 4 MG DOSEPAK: $0.292 per unitBrand · +0% in a year
Solu-MedrolDrugs with a new indication and a new dosage for the treatment of the acute phase of Kawasaki's disease (for patients with severe Kawasaki's disease who… · Pfizer Japan Inc. · Sep 25, 2023
Solu-MedrolDrugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis… · Pfizer Japan Inc. · Aug 29, 2014
Solu-MedrolDrugs with a new additional indication and a new dosage for the treatment of acute exacerbation of multiple sclerosis. · Pfizer Japan Inc. · Mar 25, 2013
Solu-MedrolDrugs with a new additional indication and a new dosage for the treatment of nephrotic syndrome. · Fuji Pharma Co., Ltd. · May 20, 2011
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA